293 related articles for article (PubMed ID: 25456072)
1. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
[TBL] [Abstract][Full Text] [Related]
2. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H
J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
[TBL] [Abstract][Full Text] [Related]
3. Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.
Matsushita M; Esaki R; Mishima K; Ishiguro N; Ohno K; Kitoh H
Sci Rep; 2017 Aug; 7(1):7371. PubMed ID: 28785080
[TBL] [Abstract][Full Text] [Related]
4. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
[TBL] [Abstract][Full Text] [Related]
5. Long-term oral meclozine administration improves survival rate and spinal canal stenosis during postnatal growth in a mouse model of achondroplasia in both sexes.
Funahashi H; Matsushita M; Esaki R; Mishima K; Ohkawara B; Kamiya Y; Takegami Y; Ohno K; Kitoh H; Imagama S
JBMR Plus; 2024 Apr; 8(4):ziae018. PubMed ID: 38544920
[TBL] [Abstract][Full Text] [Related]
6. PTH has the potential to rescue disturbed bone growth in achondroplasia.
Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
[TBL] [Abstract][Full Text] [Related]
7. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
[TBL] [Abstract][Full Text] [Related]
8. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
[TBL] [Abstract][Full Text] [Related]
9. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
[TBL] [Abstract][Full Text] [Related]
10. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
Legeai-Mallet L
Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
[TBL] [Abstract][Full Text] [Related]
11. PTH 1-34 Ameliorates the Osteopenia and Delayed Healing of Stabilized Tibia Fracture in Mice with Achondroplasia Resulting from Gain-Of-Function Mutation of FGFR3.
Chen H; Sun X; Yin L; Chen S; Zhu Y; Huang J; Jiang W; Chen B; Zhang R; Chen L; Nie M; Xie Y; Deng Z
Int J Biol Sci; 2017; 13(10):1254-1265. PubMed ID: 29104492
[TBL] [Abstract][Full Text] [Related]
12. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
Di Rocco F; Biosse Duplan M; Heuzé Y; Kaci N; Komla-Ebri D; Munnich A; Mugniery E; Benoist-Lasselin C; Legeai-Mallet L
Hum Mol Genet; 2014 Jun; 23(11):2914-25. PubMed ID: 24419316
[TBL] [Abstract][Full Text] [Related]
14. Activated FGFR3 promotes bone formation via accelerating endochondral ossification in mouse model of distraction osteogenesis.
Osawa Y; Matsushita M; Hasegawa S; Esaki R; Fujio M; Ohkawara B; Ishiguro N; Ohno K; Kitoh H
Bone; 2017 Dec; 105():42-49. PubMed ID: 28802681
[TBL] [Abstract][Full Text] [Related]
15. Activated FGFR3 prevents subchondral bone sclerosis during the development of osteoarthritis in transgenic mice with achondroplasia.
Okura T; Matsushita M; Mishima K; Esaki R; Seki T; Ishiguro N; Kitoh H
J Orthop Res; 2018 Jan; 36(1):300-308. PubMed ID: 28520086
[TBL] [Abstract][Full Text] [Related]
16. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
[TBL] [Abstract][Full Text] [Related]
17. Skeletal Characterization of the Fgfr3 Mouse Model of Achondroplasia Using Micro-CT and MRI Volumetric Imaging.
Shazeeb MS; Cox MK; Gupta A; Tang W; Singh K; Pryce CT; Fogle R; Mu Y; Weber WD; Bangari DS; Ying X; Sabbagh Y
Sci Rep; 2018 Jan; 8(1):469. PubMed ID: 29323153
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia.
Kitoh H; Matsushita M; Mishima K; Nagata T; Kamiya Y; Ueda K; Kuwatsuka Y; Morikawa H; Nakai Y; Ishiguro N
PLoS One; 2020; 15(4):e0229639. PubMed ID: 32282831
[TBL] [Abstract][Full Text] [Related]
19. Low bone mineral density in achondroplasia and hypochondroplasia.
Matsushita M; Kitoh H; Mishima K; Kadono I; Sugiura H; Hasegawa S; Nishida Y; Ishiguro N
Pediatr Int; 2016 Aug; 58(8):705-8. PubMed ID: 26716907
[TBL] [Abstract][Full Text] [Related]
20. Novel phenotype of achondroplasia due to biallelic FGFR3 pathogenic variants.
Chang IJ; Sun A; Bouchard ML; Kamps SE; Hale S; Done S; Goldberg MJ; Glass IA
Am J Med Genet A; 2018 Jul; 176(7):1675-1679. PubMed ID: 30160829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]